Newly Approved and Investigational Drugs for Motor Symptom Control in Parkinson's Disease.

ABSTRACT: Motor symptoms are a core feature of Parkinson's disease (PD) and cause a significant burden on patients' quality of life. Oral levodopa is still the most effective treatment, however, the motor benefits are countered by inherent pharmacologic limitations of the drug. Additionally, with disease progression, chronic levodopa leads to the appearance of motor complications including motor fluctuations and dyskinesia. Furthermore, several motor abnormalities of posture, balance, and gait may become less responsive to levodopa. With these unmet needs and our evolving understanding of the neuroanatomic and pathophysiologic underpinnings of PD, several advances have been made in defining new therapies for motor symptoms. These include newer levodopa formulations and drug delivery systems, refinem

SUBMITTER: Di Luca DG 

PROVIDER: S-EPMC9287529 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature